T2DiACoD: A Gene Atlas of Type 2 Diabetes Mellitus Associated Complex Disorders

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Rani, Jyoti ^a   Mittal, Inna ^a   Pramanik, Atreyi ^a   Singh, Namita ^a   Dube, Namita ^a   Sharma, Smriti ^a   Puniya, Bhanwar Lal ^a   Raghunandanan, Muthukurussi Varieth ^a   Mobeen, Ahmed ^a,b   Ramachandran, Srinivasan ^a,b  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY SPECIFICITY; COMPLICATION; DATA MINING; DIABETIC COMPLICATION; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; HUMAN; INFORMATION PROCESSING; INTERNET; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE;

DATA CURATION; DATA MINING; DATABASES, GENETIC; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERNET; MUSCLE, SKELETAL; ORGAN SPECIFICITY; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 85026557006     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-07238-0     Document Type: Article

References (181)

1. Ashcroft, F. M. & Rorsman, P. Diabetes mellitus and the beta cell: The last ten years. Cell 148, 1160-1171 (2012).
2. Prasad, R. B. & Groop, L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes (Basel). 6, 87-123 (2015).
3. Patel, C. J. et al. Systematic identification of interaction effects between genome- and environment-wide associations in type 2 diabetes mellitus. Human genetics 132(5), 495-508 (2013).
4. Schwartz, D. & Collins, F. Environmental biology and human disease. Science 316(5825), 695-696 (2007).
5. Einstein: Albert Einstein College of Medicine - diabetes facts and statistics. https://www.einstein.yu.edu/centers/diabetes-research/facts-statistics/ Date of Access: 20/11/2015 (2015).
6. Miloš, S. et al. Repeated low-dose 17β-estradiol treatment prevents activation of apoptotic signaling both in the synaptosomal and cellular fraction in rat prefrontal cortex following cerebral ischemia. Neurochemistry international 83, 1-8 (2015).
7. Prokopenko, I., McCarthy, M. I. & Lindgren, C. M. Type 2 diabetes: new genes, new understanding. Trends Genet. 24, 613-21 (2008).
8. Teslovich, T. M. et al. Re-sequencing expands our understanding of the phenotypic impact of variants at GWAS loci. PLoS Genet 10, 1 (2014).
9. Patel, C. J., Chen, R., Kodama, K., Ioannidis, J. P. A. & Butte, A. J. Systematic identification of interaction effects between validated genome- and environment-wide associations on Type 2 Diabetes Mellitus. AMIA Jt. Summits Transl. Sci. Proc. AMIA Summit Transl. Sci. 2013, 135 (2013).
10. Lyssenko, V. et al. Genetic screening for the risk of type 2 diabetes: worthless or valuable? Diabetes Care 36(Suppl 2), S120-6 (2013).
11. Palmer, N. D. et al. A genome-wide association search for type 2 diabetes genes in african americans. PLoS One 7 (2012).
12. Wheeler, E. & Barroso, I. Genome-wide association studies and type 2 diabetes. Brief. Funct. Genomics 10, 52-60 (2011).
13. Hakonarson, H. & Grant, S. F. Genome-wide association studies (GWAS): impact on elucidating the aetiology of diabetes. Diabetes/metabolism research and reviews 27(7), 685-696 (2011).
14. Fuchsberger, C. et al. The genetic architecture of type 2 diabetes. Nature 536, 41-7 (2016).
15. Sreekumar, R., Halvatsiotis, P., Schimke, J. C. & Sreekumaran Nair, K. Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 51, 1913-1920 (2002).
16. Nair, S. et al. Increased expression of inflammation-related genes in cultured preadipocytes/stromal vascular cells from obese compared with non-obese Pima Indians. Diabetologia 48(9), 1784-1788 (2005).
17. Zelezniak, A., Pers, T. H., Soares, S., Patti, M. E. & Patil, K. R. Metabolic network topology reveals transcriptional regulatory signatures of type 2 diabetes. PLoS Comput. Biol. 6, e1000729 (2010).
18. Sengupta, U., Ukil, S., Dimitrova, N. & Agrawal, S. Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications. PloS one 4(12), e8100 (2009).
19. Zhong, H. et al. Liver and Adipose Expression Associated SNPs Are Enriched for Association to Type 2 Diabetes. Plos Genet. 6, 12 (2010).
20. Herzig, S. Liver: A target of late diabetic complications. Experimental and Clinical Endocrinology and Diabetes 120, 202-204 (2012).
21. Shore, A. C. et al. Measures of atherosclerotic burden are associated with clinically manifest cardiovascular disease in type 2 diabetes: A European cross-sectional study. J. Intern. Med. 278, 291-302 (2015).
22. Korish, A. A. et al. Camel milk attenuates the biochemical and morphological features of diabetic nephropathy: inhibition of Smad1 and collagen type IV synthesis. Chemico-biological interactions 229, 100-108 (2015).
23. Gandhi, C. R. & Ross, D. H. Microwave induced stimulation of 32Pi incorporation into phosphoinositides of rat brain synaptosomes. Radiat. Environ. Biophys. 28, 223-234 (1989).
24. Park, E. I. et al. Lipid level and type alter stearoyl CoA desaturase mRNA abundance differently in mice with distinct susceptibilities to diet-influenced diseases. J. Nutr. 127, 566-573 (1997).
25. Hegele, R. A. et al. The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management. The Lancet Diabetes and Endocrinology 2, 655-666 (2014).
26. Carpena, M. P. et al. Genetics of diabetic nephropathy. Arquivos Brasileiros de Endocrinologia & Metabologia 54(3), 253-261 (2010).
27. Gohda, T. et al. Genetic susceptibility to type 2 diabetic nephropathy in human and animal models. Nephrology 10(s2), S22-S25 (2005).
28. Dobrowsky, R. T., Rouen, S. & Yu, C. Altered neurotrophism in diabetic neuropathy: spelunking the caves of peripheral nerve. J. Pharmacol. Exp. Ther. 313, 485-491 (2005).
29. Arar, N. H. et al. Heritability of the severity of diabetic retinopathy: The FIND-Eye study. Investig. Ophthalmol. Vis. Sci. 49, 3839-3845 (2008).
30. Narne, P., Ponnaluri, K. C., Siraj, M. & Ishaq, M. Association Analysis of Polymorphisms in Genes Related to Oxidative Stress in South Indian Type 2 Diabetic Patients with Retinopathy. Ophthalmic Genet. 1-8, doi: 10.3109/13816810.2014.895015 (2014).
31. Bessueille, L. & Magne, D. Inflammation: a culprit for vascular calcification in atherosclerosis and diabetes. Cell. Mol. Life Sci. 72, 2475-2489 (2015).
32. Yoo, H. J. & Choi, K. M. Hepatokines as a link between obesity and cardiovascular diseases. Diabetes and Metabolism Journal 39, 10-15 (2015).
33. Agrawal, S. et al. T2D-Db: an integrated platform to study the molecular basis of Type 2 diabetes. BMC genomics 9(1), 320 (2008).
34. Lim, J. E. et al. Type 2 diabetes genetic association database manually curated for the study design and odds ratio. BMC medical informatics and decision making 10(1), 76 (2010).
35. Dai, H. J., Wu, J. C. Y., Tsai, R. T. H., Pan, W. H. & Hsu, W. L. T-HOD: A literature-based candidate gene database for hypertension, obesity and diabetes. Database 2013 (2013).
36. Piñero, J. et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. http://www.disgenet.org/web/DisGeNET/menu Database, Date of access: 13/01/2016 (2015).
37. Agrawal, S. et al. T2D-Db: an integrated platform to study the molecular basis of Type 2 diabetes. http://t2ddb.ibab.ac.in/home.shtml BMC genomics 9(1), 320, Date of Access: 13/01/2016 (2008).
38. T2D-GENES Consortium, GoT2D Consortium, DIAGRAM Consortium. 2017, May, Available at http://www.type2diabetesgenetics.org/.
39. Li, W. B. et al. Silencing of activin receptor-like kinase 7 alleviates aortic stiffness in type 2 diabetic rats. Acta Diabetol. 52, 717-726 (2015).
40. Connelly, P. W. et al. Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes. J. Lipid Res. 50, 1216-1222 (2009).
41. Barathi, S., Charanya, M., Muthukumaran, S., Angayarkanni, N. & Umashankar, V. Comparative modeling of PON2 and analysis of its substrate binding interactions using computational methods. J. Ocul. Biol. Dis. Infor. 3, 64-72 (2010).
42. Ikeda, Y. et al. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol. 46, 239-242 (2009).
43. Odeberg, J., Larsson, C. A., Rastam, L. & Lindblad, U. The Asp(298) allele of endothelial nitric oxide synthase is a risk factor for myocardial infarction among patients with type 2 diabetes mellitus. BMC Cardiovasc. Disord. 8 (2008).
44. Blázquez-Medela, A. M. et al. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. European journal of clinical investigation 42(5), 548-556 (2012).
45. Katakami, N. et al. Adiponectin G276T gene polymorphism is associated with cardiovascular disease in Japanese patients with type 2 diabetes. Atherosclerosis 220(2), 437-442 (2012).
46. Yan, X. X. et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 205(2), 544-548 (2009).
47. Strawbridge, R. J. et al. serum 25-hydroxyvitamin D concentration-associated genetic variant in DHCR7 interacts with type 2 diabetes status to influence subclinical atherosclerosis (measured by carotid intima-media thickness). Diabetologia 57(6), 1159-1172 (2014).
48. Kim, M. K. et al. Clinical utility of serum beta-2-microglobulin as a predictor of diabetic complications in patients with type 2 diabetes without renal impairment. Diabetes & metabolism 40(6), 459-465 (2014).
49. Chang, Y. C. et al. Hyperglycemia accelerates ATP-binding cassette transporter A1 degradation via an ERK-dependent pathway in macrophages. Journal of cellular biochemistry 114(6), 1364-1373 (2013).
50. Oram, J. F. & Heinecke, J. W. ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 85, 1343-1372 (2005).
51. Kyriakou, T. et al. Genotypic effect of the-565C >T polymorphism in the ABCA1 gene promoter on ABCA1 expression and severity of atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 25(2), 418-423 (2005).
52. Sartippour, M. R. & Renier, G. Differential regulation of macrophage peroxisome proliferator-activated receptor expression by glucose: role of peroxisome proliferator-activated receptors in lipoprotein lipase gene expression. Arter. Thromb Vasc Biol 20, 104-110 (2000).
53. Wang, X. Q., Yang, K., He, Y. S., Lu, L. & Shen, W. F. Receptor mediated elevation in FABP4 levels by advanced glycation end products induces cholesterol and triacylglycerol accumulation in THP-1 macrophages. Lipids 46, 479-486 (2011).
54. Nakamura, A. et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes care 28(12), 2890-2895 (2005).
55. Zhang, W. et al. The functional Q84R polymorphism of TRIB3 gene is associated with diabetic nephropathy in Chinese type 2 diabetic patients. Gene 555(2), 357-361 (2015).
56. Zhang, L. et al. Down-regulation of miR-34a alleviates mesangial proliferation in vitro and glomerular hypertrophy in early diabetic nephropathy mice by targeting GAS1. Journal of Diabetes and its Complications 28(3), 259-264 (2014).
57. Stefanidis, I. et al. Association Between the Interleukin-1β Gene (IL1B) C-511T Polymorphism and the Risk of Diabetic Nephropathy in Type 2 Diabetes: A Candidate-Gene Association Study. DNA and cell biology 33(7), 463-468 (2014).
58. Hookham, M. B. et al. Insulin receptor substrate-2 is expressed in kidney epithelium and up-regulated in diabetic nephropathy. FEBS journal 280(14), 3232-3243 (2013).
59. Bonomo, J. A. et al. The ras responsive transcription factor RREB1 is a novel candidate gene for type 2 diabetes associated end-stage kidney disease. Human molecular genetics 23(24), 6441-6447 (2014).
60. Shcherbak, N. S., Shutskaya, Z. V., Sheidina, A. M., Larionova, V. I. & Schwartz, E. I. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Mol. Genet. Metab. 68, 375-378 (1999).
61. Mazza, A. et al. Serum homocysteine, MTHFR gene polymorphism, and carotid intimal-medial thickness in NIDDM subjects. Journal of thrombosis and thrombolysis 8(3), 207-212 (1999).
62. Abu El-Asrar, A. M., Mairaj Siddiquei, M., Nawaz, M. I., Geboes, K. & Mohammad, G. The proinflammatory cytokine high-mobility group box-1 mediates retinal neuropathy induced by diabetes. Mediators Inflamm. 2014 (2014).
63. Simon, C. M. et al. Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy. Acta neuropathologica 130(3), 373-387 (2015).
64. Hellweg, R. & Hartung, H. D. Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. Journal of neuroscience research 26(2), 258-267 (1990).
65. Faradji, V. & Sotelo, J. Low serum levels of nerve growth factor in diabetic neuropathy. Acta Neurol. Scand. 81, 402-406 (1990).
66. Hernández-Pedro, N. et al. Vitamin A increases nerve growth factor and retinoic acid receptor beta and improves diabetic neuropathy in rats. Translational Research 164(3), 196-201 (2014).
67. Burdon, K. P. et al. Genome-wide association study for sight-threatening diabetic retinopathy reveals association with genetic variation near the GRB2 gene. Diabetologia 58(10), 2288-2297 (2015).
68. Yamaji, Y. et al. TEM7 (PLXDC1) in neovascular endothelial cells of fibrovascular membranes from patients with proliferative diabetic retinopathy. Investigative ophthalmology & visual science 49(7), 3151-3157 (2008).
69. Pradeepa, R. et al. Association of serum adiponectin with diabetic microvascular complications among south Indian type 2 diabetic subjects - (CURES-133). Clin. Biochem. 48, 33-38 (2015).
70. Niu, W. et al. A meta-analysis of receptor for advanced glycation end products gene: Four well-evaluated polymorphisms with diabetes mellitus. Mol. Cell. Endocrinol. 358, 9-17 (2012).
71. Katakami, N. et al. Adiponectin G276T gene polymorphism is associated with cardiovascular disease in Japanese patients with type 2 diabetes. Atherosclerosis 220, 437-42 (2012).
72. Fredriksson, J. et al. Variation in GYS1 interacts with exercise and gender to predict cardiovascular mortality. PLoS One 2 (2007).
73. M., G. et al. The relationship of ACE and CETP gene polymorphisms with cardiovascular disease in a cohort of Asian Indian patients with and those without type 2 diabetes. J. Diabetes Complications 25, 303-308 (2011).
74. Wu, S. S. et al. The relationship of angiotensin I-converting enzyme gene polymorphism with diabetic retinopathy and diabetes myocardial infarction. Zhonghua yi xue yi chuan xue za zhi=Zhonghua yixue yichuanxue zazhi=Chinese journal of medical genetics 21(3), 283-285 (2004).
75. Ait-Oufella, H. et al. Recent advances on the role of cytokines in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 31(5), 969-979 (2011).
76. Solini, A., Santini, E., Nannipieri, M. & Ferrannini, E. High glucose and homocysteine synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts. Diabetologia 49, 2499-2506 (2006).
77. Hodgkinson, C. P., Laxton, R. C., Patel, K. & Ye, S. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 28, 2275-2281 (2008).
78. Cooper, M. E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet (London, England) 352, 213-9 (1998).
79. Cooper, M. E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 44, 1957-1972 (2001).
80. Pálsson, R. & Patel, U. D. Cardiovascular complications of diabetic kidney disease. Adv. Chronic Kidney Dis. 21 (2014).
81. Ni, W. J., Tang, L. Q. & Wei, W. Research progress in signalling pathway in diabetic nephropathy. Diabetes/metabolism research and reviews 31(3), 221-233 (2015).
82. Raptis, A. E. & Viberti, G. Pathogenesis of diabetic nephropathy. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology and German Diabetes Association 109, S424-37 (2000).
83. Luo, J. et al. TCF7L2 variation and proliferative diabetic retinopathy. Diabetes 62, 2613-2617 (2013).
84. Hughes, J. M. et al. Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia 50, 1089-1098 (2007).
85. Kaidonis, G. et al. Common Sequence Variation in the VEGFC Gene Is Associated with Diabetic Retinopathy and Diabetic Macular Edema. Ophthalmology 122, 1828-1836 (2015).
86. Østergaard, L. et al. The effects of capillary dysfunction on oxygen and glucose extraction in diabetic neuropathy. Diabetologia 58(4), 666-677 (2015).
87. Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L. & Feldman, E. L. Diabetic neuropathy: Clinical manifestations and current treatments. The Lancet Neurology 11, 521-534 (2012).
88. Cameron, N. E., Eaton, S. E., Cotter, M. A. & Tesfaye, S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44, 1973-1988 (2001).
89. Tsuzuki, S. et al. The examination of apoE phenotypes in diabetic patients with peripheral neuropathy. Rinsho Byori. 46, 829-833 (1998).
90. Vincent, A. M. et al. SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Exp. Neurol. 208, 216-227 (2007).
91. Wang, L. et al. Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. Neuroscience 193, 399-410 (2011).
92. Bhatia, H., Verma, G. & Datta, M. MiR-107 orchestrates ER stress induction and lipid accumulation by post-transcriptional regulation of fatty acid synthase in hepatocytes. Biochim. Biophys. Acta - Gene Regul. Mech. 1839, 334-343 (2014).
93. Wijesekara, N. et al. miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes 61, 653-658 (2012).
94. Párrizas, M. et al. Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention. J. Clin. Endocrinol. Metab. 100, E407-E415 (2015).
95. Bang-Berthelsen, C. H. et al. Independent component and pathway-based analysis of miRNA-regulated gene expression in a model of type 1 diabetes. BMC Genomics 12, 97 (2011).
96. Kornfeld, J.-W. et al. Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b. Nature 494, 111-5 (2013).
97. Higuchi, C. et al. Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes. Metabolism 64(4), 489-497 (2015).
98. Olivieri, F. et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget 6, 35372-35382 (2015).
99. Ling, H. Y. et al. MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3T3-L1 adipocytes through targeting phosphatase and tensin homologue. Exp. Clin. Endocrinol. Diabetes 120, 553-559 (2012).
100. Zhou, B. et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 55, 2032-2043 (2012).
101. Locke, J. M., Lango Allen, H. & Harries, L. W. A rare SNP in pre-miR-34a is associated with increased levels of miR-34a in pancreatic beta cells. Acta Diabetol. 51, 325-329 (2014).
102. Corral-Fernández, N. E. et al. Dysregulated miR-155 expression in peripheral blood mononuclear cells from patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 121, 347-53 (2013).
103. Miller, A. M. et al. MiR-155 Has a Protective Role in the Development of Non-Alcoholic Hepatosteatosis in Mice. PLoS One 8 (2013).
104. Sebastiani, G. et al. MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetol. 52, 523-530 (2015).
105. Karolina, D. S. et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One 6 (2011).
106. Wang, X. et al. Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PloS one 9(1) (2014).
107. Zhang, Y. et al. MicroRNA-106b induces mitochondrial dysfunction and insulin resistance in C2C12 myotubes by targeting mitofusin-2. Molecular and cellular endocrinology 381(1), 230-240 (2013).
108. Wu, Y. et al. Identification of miR-106b-93 as a negative regulator of brown adipocyte differentiation. Biochem. Biophys. Res. Commun. 438, 575-580 (2013).
109. Setyowati Karolina, D., Sepramaniam, S., Tan, H. Z., Armugam, A. & Jeyaseelan, K. miR-25 and miR-92a regulate insulin I biosynthesis in rats. RNA Biol. 10, 1365-78 (2013).
110. Hou, X., Wu, W., Yin, B., Liu, X. & Ren, F. MicroRNA-463-3p/ABCG4: A new axis in glucose-stimulated insulin secretion. Obesity 24(11), 2368-2376 (2016).
111. Latouche, C. et al. MicroRNA-194 modulates glucose metabolism and its skeletal muscle expression is reduced in diabetes. PLoS One 11 (2016).
112. Yang, W. M., Jeong, H. J., Park, S. W. & Lee, W. Obesity-induced miR-15b is linked causally to the development of insulin resistance through the repression of the insulin receptor in hepatocytes. Mol. Nutr. Food Res. 59, 2303-2314 (2015).
113. Shan, Q. et al. Epigenetic modification of miR-10a regulates renal damage by targeting CREB1 in type 2 diabetes mellitus. Toxicol. Appl. Pharmacol. 306, 134-143 (2016).
114. Luo, B. et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One 9(8) (2014).
115. Ma, B. et al. Cardiac-specific overexpression of CYP2J2 attenuates diabetic cardiomyopathy in male streptozotocin-induced diabetic mice. Endocrinology 154(8), 2843-2856 (2013).
116. Geloen, A. et al. CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis. PLoS One 7(5), e37633 (2012).
117. Zheng, H. et al. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60(11), 3055-3066 (2011).
118. Fan, J. & Xu, G. Heme oxygenase-1 mediates Nrf2-dependent protection of neurons and vascular endothelial cells in diabetic retinopathy. Investigative Ophthalmology & Visual Science 52(14), 4446-4446 (2011).
119. Negi, G., Kumar, A. & Sharma, S. S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades. Journal of pineal research 50(2), 124-131 (2011).
120. Zhang, W. et al. Changes of angiotensin converting enzyme 2 in the occurrence and development of diabetic renal injury in rat. Sheng li xue bao: Acta physiologica Sinica 65(4), 402-408 (2013).
121. Verma, A. et al. ACE2 and Ang-(1-7) confer protection against development of diabetic retinopathy. Molecular Therapy 20(1), 28-36 (2012).
122. Szabadfi, K. et al. Protective effects of the neuropeptide PACAP in diabetic retinopathy. Cell and tissue research 348(1), 37-46 (2012).
123. Dadras, F. & Khoshjou, F. NF-E2-related factor 2 and its role in diabetic nephropathy. Iranian journal of kidney diseases 7(5), 346 (2013).
124. Liu, Q. et al. Therapeutic effects of suppressors of cytokine signaling in diabetic nephropathy. Journal of Histochemistry & Cytochemistry 62(2), 119-128 (2014).
125. Papadimitriou, A. et al. Increase in AMPK brought about by cocoa is renoprotective in experimental diabetes mellitus by reducing NOX4/TGFβ-1 signaling. The Journal of nutritional biochemistry 25(7), 773-784 (2014).
126. Li, R. et al. Angelica injection promotes peripheral nerve structure and function recovery with increased expressions of nerve growth factor and brain derived neurotrophic factor in diabetic rats. Current neurovascular research 7(3), 213-222 (2010).
127. Yang, S. et al. Experimental study of the protective effects of SYVN1 against diabetic retinopathy. Scientific reports 5 (2015).
128. Perrone, L., Devi, T. S., Hosoya, K. I., Terasaki, T. & Singh, L. P. Inhibition of TXNIP expression in vivo blocks early pathologies of diabetic retinopathy. Cell death & disease 1(8), 65 (2010).
129. Atkinson, B. J., Griesel, B. A., King, C. D., Josey, M. A. & Olson, A. L. Moderate glut4 overexpression improves insulin sensitivity and fasting triglyceridemia in high-fat diet-fed transgenic mice. Diabetes 62, 2249-2258 (2013).
130. Shi, S. Y. et al. Adipocyte-specific deficiency of Janus kinase (JAK) 2 in mice impairs lipolysis and increases body weight, and leads to insulin resistance with ageing. Diabetologia 57, 1016-1026 (2014).
131. Araoka, T. et al. Transcription factor 7-like 2 (TCF7L2) regulates activin receptor-like kinase 1 (ALK1)/Smad1 pathway for development of diabetic nephropathy. Mol. Cells 30, 209-218 (2010).
132. Muendlein, A. et al. Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis. PLoS One 6 (2011).
133. Luo, J. et al. TCF7L2 variation and proliferative diabetic retinopathy. Diabetes 62, 2613-2617 (2013).
134. Miyata, T. et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 244, 45-49 (1998).
135. Yousefzadeh, G., Pezeshki, S., Gholamhosseinian, A., Nazemzadeh, M. & Shokoohi, M. Plasma cystatin-C and risk of developing gestational diabetes mellitus. Diabetes Metab. Syndr. Clin. Res. Rev. 8, 33-35 (2014).
136. Li, L. et al. Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res. Clin. Pract. 82, 209-213 (2008).
137. Mahmoud, R. A. K., el-Ezz, S. A. A. & Hegazy, A. S. Increased serum levels of interleukin-18 in patients with diabetic nephropathy. Ital. J. Biochem. 53, 73-81 (2004).
138. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 29, 43-48 (2006).
139. Sindelar, D. K. et al. Low plasma leptin levels contribute to diabetic hyperphagia in rats. Diabetes 48(6), 1275-1280 (1999).
140. Sun, L. et al. Elevated plasma retinol-binding protein 4 is associated with increased risk of type 2 diabetes in middle-aged and elderly Chinese adults. J. Nutr. 144, 722-728 (2014).
141. Jguirim-Souissi, I. et al. Plasma Metalloproteinase-12 and Tissue Inhibitor of Metalloproteinase-1 Levels and Presence, Severity, and Outcome of Coronary Artery Disease. Am. J. Cardiol. 100, 23-27 (2007).
142. Thomsen, S. B., Rathcke, C. N., Zerahn, B. & Vestergaard, H. Increased levels of the calcification marker Matrix Gla Protein and the inflammatory markers YKL-40 and CRP in patients with type 2 diabetes and ischemic heart disease. Cardiovasc. Diabetol. 9, 7 (2010).
143. Li, Q. et al. Serum Angptl2 levels are independently associated with albuminuria in type 2 diabetes. Diabetes Res. Clin. Pract. 100, 385-390 (2013).
144. Makino, A. et al. High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 213(2), 573-578 (2010).
145. Lim, H. S. et al. Plasma Vascular Endothelial Growth Factor, Angiopoietin-1, and Angiopoietin-2 in Diabetes Implications for cardiovascular risk and effects of multifactorial intervention. Diabetes Care 27(12), 2918-2924 (2004).
146. Tjeerdema, N. et al. Inflammation increases plasma angiopoietin-like protein 4 in patients with the metabolic syndrome and type 2 diabetes. BMJ open diabetes Res. care 2, e000034 (2014).
147. Jong, M. C. et al. Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 50, 2779-2785 (2001).
148. Kamoi, K., Ishibashi, M. & Yamaji, T. Thirst and plasma levels of vasopressin, angiotensin II and atrial natriuretic peptide in patients with non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 11, 195-202 (1991).
149. Yang, B., Hodgkinson, A. D., Shaw, N. A., Millward, B. A. & Demaine, A. G. Protective effect of statin therapy on connective tissue growth factor induction by diabetes in vivo and high glucose in vitro. Growth Factors 31, 199-208 (2013).
150. Wong, C. K. et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin. Exp. Immunol. 149, 123-131 (2007).
151. Németh, B. C. et al. Relevance of α-defensins (HNP1-3) and defensin β-1 in diabetes. World journal of gastroenterology: WJG 20(27), 9128 (2014).
152. Lee, I. J. et al. Growth arrest-specific gene 6 (Gas6) levels are elevated in patients with chronic renal failure. Nephrol. Dial. Transplant. 27, 4166-4172 (2012).
153. Müller, I. I. et al. Impact of counterbalance between macrophage migration inhibitory factor and its inhibitor Gremlin-1 in patients with coronary artery disease. Atherosclerosis 237, 426-432 (2014).
154. Zhang, X.-J. et al. Expression status of diabetes-associated genes in middle and aged cynomolgus monkeys. Zool. Res. 32, 300-6 (2011).
155. Narayanan, R. P. et al. IGFBP2 is a biomarker for predicting longitudinal deterioration in renal function in type 2 diabetes. Endocrine Connections 2(1), X1 (2013).
156. Bulló, M., Peeraully, M. R., Trayhurn, P., Folch, J. & Salas-Salvadó, J. Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur. J. Endocrinol. 157, 303-10 (2007).
157. Bacon, S. et al. Serum levels of pancreatic stone protein (PSP)/reg1A as an indicator of beta-cell apoptosis suggest an increased apoptosis rate in hepatocyte nuclear factor 1 alpha (HNF1A-MODY) carriers from the third decade of life onward. BMC endocrine disorders 12(1), 13 (2012).
158. Yildirim, N. et al. The relationship between plasma MMP-9 and TIMP-2 levels and intraocular pressure elevation in diabetic patients after intravitreal triamcinolone injection. J. Glaucoma 17, 253-6 (2008).
159. (A.D.A.M. Medical Encyclopedia [Internet]. Atlanta (GA): A.D.A.M., Inc.; © 1997-2017. Nail abnormalities; [updated 2017 May 9]. Available at: https://medlineplus.gov/ency/article/000313.htm).
160. Rani, J., Shah, A.R. and Ramachandran, S. pubmed. mineR: An R package with text-mining algorithms to analyse PubMed abstracts. https://cran.r-project.org/web/packages/pubmed.mineR/index.html Journal of biosciences 40(4), 671-682 (2015).
161. Smith, G. K. limma: Linear Models for Microarray Data. Bioinforma. Comput. Biol. Solut. Using R Bioconductor 397-420, doi: citeulike-article-id:5722720 (2005).
162. Fellows, I. wordcloud: Word clouds. R package version 2 https://cran.r-project.org/web/packages/wordcloud/index.html Date of access: 09/09/2015 (2012).
163. Melville S. NCBI2R-An R package to navigate and annotate genes and SNPs https://github.com/cran/NCBI2R; Date of access: 15/07/2014 (2012).
164. Jensen, L. J., Saric, J. & Bork, P. Literature mining for the biologist: from information retrieval to biological discovery. Nat. Rev. Genet. 7, 119-29 (2006).
165. Barrett, T. et al. NCBI GEO: mining millions of expression profiles - database and tools https://www.ncbi.nlm.nih.gov/geo/ Nucleic acids research 33(suppl 1), D562-D566 Date of Access: 10/11/2015 (2005).
166. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. Affy - Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307-315 (2004).
167. Du, P., Kibbe, W. A. & Lin, S. M. lumi: A pipeline for processing Illumina microarray. Bioinformatics 24, 1547-1548 (2008).
168. Iglewicz, B. and Hoaglin, D.C. How to detect and handle outliers (Vol. 16). Asq Press (1993).
169. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).
170. Ferland-McCollough, D., Ozanne, S. E., Siddle, K., Willis, A. E. and Bushell, M. The involvement of microRNAs in Type 2 diabetes (2010).
171. Dennis, G. Jr. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4, P3 (2003).
172. Merico, D., Isserlin, R., Stueker, O., Emili, A. & Bader, G. D. Enrichment map: A network-based method for gene-set enrichment visualization and interpretation. PLoS One 5 (2010).
173. Stamm, S. et al. ASD: a bioinformatics resource on alternative splicing. Nucleic acids research 34(suppl 1), pp. D46-D55 (2006).
174. Matys, V. et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 34, D108-10 (2006).
175. Grillo, G. et al. UTRdb and UTRsite (RELEASE 2010): A collection of sequences and regulatory motifs of the untranslated regions of eukaryotic mRNAs. Nucleic Acids Res. 38 (2009).
176. Mandal, M. & Breaker, R. R. Gene regulation by riboswitches. Nat. Rev. Mol. Cell Biol. 5, 451-463 (2004).
177. Griffiths-Jones, S. et al. Rfam: annotating non-coding RNAs in complete genomes. Nucleic acids research 33(suppl 1), pp D121-D124 (2005).
178. Kin, T. et al. fRNAdb: a platform for mining/annotating functional RNA candidates from non-coding RNA sequences. Nucleic acids research. 35(suppl 1), D145-D148 (2007).
179. Macke, T. J. et al. RNAMotif, an RNA secondary structure definition and search algorithm. Nucleic Acids Res. 29, 4724-4735 (2001).
180. Huang, H. Y., Chien, C. H., Jen, K. H. & Huang, H. D. RegRNA: An integrated web server for identifying regulatory RNA motifs and elements. Nucleic Acids Res. 34 (2006).
181. The UniProt Consortium. UniProt: a hub for protein information. Nucleic Acids Res. 43, D204-12 (2015).